Clover Health Partners with CMS for Data Interoperability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CLOV?
Clover Health Investments announced a collaboration enabling Clover Health to be the first payer live on a CMS Aligned Network and TEFCA. Clover is demonstrating that nationwide, interoperable data exchange is not aspirational, it is achievable today. Through this collaboration, Clover Health now responds in real time to patient-directed requests for clinical and claims data using standardized FHIR formats. The milestone advances CMS's vision for aligned networks and TEFCA's IAS implementation, enabling patients to securely authenticate and request their health information from any participating payer through a connected network.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.000
Low
3.00
Averages
3.35
High
3.70
Current: 2.000
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clover Health Partners with Kno2 for Real-Time Data Interoperability
- Real-Time Data Interoperability: Clover Health becomes the first payer to respond in real-time to patient requests on a CMS Aligned Network and TEFCA, utilizing standardized FHIR formats to enhance patient access to clinical and claims data, marking a significant achievement in nationwide interoperable data exchange.
- Technological Infrastructure Advantage: Powered by its subsidiary Counterpart Health, Clover Health ensures secure and efficient routing of patient requests across the CMS Aligned Network, facilitating coordination among care teams and improving the quality of value-based healthcare services.
- Industry Benchmark Role: Clover Health's early adoption signals that interoperable, patient-directed data exchange is not only feasible but achievable, driving the healthcare industry towards more efficient data management practices.
- Demonstration Event Schedule: Clover Health, Kno2, and Counterpart Health will conduct live demonstrations at HIMSS 2026 from March 10-12, showcasing how patient requests flow through the network and return structured clinical and claims data, further validating their technological capabilities.
See More
United Airlines and Clover Health Options Trading Active
- United Airlines Options Volume: As of today, United Airlines (UAL) options volume reached 32,010 contracts, representing approximately 3.2 million shares, which is about 55.3% of its average daily trading volume over the past month, indicating significant market interest.
- High Volume Contracts: Notably, the $125 strike call option expiring on March 20, 2026, has seen 1,966 contracts traded today, equating to approximately 196,600 underlying shares, reflecting investor expectations for future price increases.
- Clover Health Options Activity: Clover Health (CLOV) options trading volume stands at 31,299 contracts, representing around 3.1 million shares or approximately 53.7% of its average daily trading volume over the past month, showcasing the stock's market activity.
- Key Contract Insights: The $2.50 strike call option expiring on March 6, 2026, has recorded a trading volume of 6,629 contracts today, amounting to approximately 662,900 shares, indicating investor confidence in the stock's short-term upward potential.
See More
CLOVER HEALTH INVESTMENTS CORP: UBS Lowers Price Target to $2.75 from $3
Company Overview: Clover Health Investments Corp is a healthcare company focused on providing Medicare Advantage plans.
Target Price Adjustment: The company has had its target price cut to $2.75 from $3 by UBS, indicating a reassessment of its market value.
See More
Clover Health (CLOV) Q4 2025 Earnings Transcript
See More
Clover Health Reports Strong 2025 Earnings and Growth Outlook
- Profitability Improvement: Clover Health achieved adjusted EBITDA profitability in 2025, with insurance revenue reaching $1.9 billion, a 41% year-over-year increase, demonstrating significant success in medical cost control and membership growth, and expects to achieve GAAP net income profitability for the first time in 2026.
- Strong Membership Growth: By the end of 2025, Clover's Medicare Advantage membership increased by 38% year-over-year to approximately 140,000 members, reflecting enhanced competitive positioning in the market, with expectations for membership to grow further to between 154,000 and 158,000 in 2026.
- Significant Revenue Growth: Insurance revenue for Q4 2025 was $486 million, a 47% year-over-year increase, while total revenue grew by 40%, showcasing Clover's market leadership, with projected total revenue for 2026 expected to reach between $2.810 billion and $2.920 billion, reflecting a 49% growth.
- Effective Cost Management: Clover reported a consolidated gross profit of $356 million for 2025, with adjusted SG&A as a percentage of total revenue improving to 20% in Q4, indicating ongoing efforts in cost control and operational efficiency, thereby strengthening the foundation for future profitability.
See More
Clover Health Projects 2026 Revenue Above Consensus Estimates
- Optimistic Revenue Outlook: Clover Health projects 2026 revenue between $2.81 billion and $2.92 billion, exceeding the consensus estimate of $2.74 billion, indicating strong confidence in future growth that may attract more investor interest.
- Significant Membership Growth: The company anticipates Medicare Advantage membership to reach 154,000 to 158,000 in 2026, representing approximately 46% year-over-year growth, which highlights substantial progress in market expansion and customer acquisition.
- Increased Cost Pressures: Despite revenue growth, Clover Health's total operating costs surged nearly 50% year-over-year to $537 million in the latest quarter, leading to a widened net loss of $0.10 per share, indicating challenges in profitability.
- Cash Flow Status: As of the end of 2025, the company reported cash, cash equivalents, and investments totaling $319.9 million, down from $437.6 million on December 31, 2024, reflecting the need for careful cash flow management during its expansion phase.
See More
Clover Health Partners with Kno2 for Real-Time Data Interoperability
- Real-Time Data Interoperability: Clover Health becomes the first payer to respond in real-time to patient requests on a CMS Aligned Network and TEFCA, utilizing standardized FHIR formats to enhance patient access to clinical and claims data, marking a significant achievement in nationwide interoperable data exchange.
- Technological Infrastructure Advantage: Powered by its subsidiary Counterpart Health, Clover Health ensures secure and efficient routing of patient requests across the CMS Aligned Network, facilitating coordination among care teams and improving the quality of value-based healthcare services.
- Industry Benchmark Role: Clover Health's early adoption signals that interoperable, patient-directed data exchange is not only feasible but achievable, driving the healthcare industry towards more efficient data management practices.
- Demonstration Event Schedule: Clover Health, Kno2, and Counterpart Health will conduct live demonstrations at HIMSS 2026 from March 10-12, showcasing how patient requests flow through the network and return structured clinical and claims data, further validating their technological capabilities.
See More
United Airlines and Clover Health Options Trading Active
- United Airlines Options Volume: As of today, United Airlines (UAL) options volume reached 32,010 contracts, representing approximately 3.2 million shares, which is about 55.3% of its average daily trading volume over the past month, indicating significant market interest.
- High Volume Contracts: Notably, the $125 strike call option expiring on March 20, 2026, has seen 1,966 contracts traded today, equating to approximately 196,600 underlying shares, reflecting investor expectations for future price increases.
- Clover Health Options Activity: Clover Health (CLOV) options trading volume stands at 31,299 contracts, representing around 3.1 million shares or approximately 53.7% of its average daily trading volume over the past month, showcasing the stock's market activity.
- Key Contract Insights: The $2.50 strike call option expiring on March 6, 2026, has recorded a trading volume of 6,629 contracts today, amounting to approximately 662,900 shares, indicating investor confidence in the stock's short-term upward potential.
See More
CLOVER HEALTH INVESTMENTS CORP: UBS Lowers Price Target to $2.75 from $3
Company Overview: Clover Health Investments Corp is a healthcare company focused on providing Medicare Advantage plans.
Target Price Adjustment: The company has had its target price cut to $2.75 from $3 by UBS, indicating a reassessment of its market value.
See More
Clover Health (CLOV) Q4 2025 Earnings Transcript
See More
Clover Health Reports Strong 2025 Earnings and Growth Outlook
- Profitability Improvement: Clover Health achieved adjusted EBITDA profitability in 2025, with insurance revenue reaching $1.9 billion, a 41% year-over-year increase, demonstrating significant success in medical cost control and membership growth, and expects to achieve GAAP net income profitability for the first time in 2026.
- Strong Membership Growth: By the end of 2025, Clover's Medicare Advantage membership increased by 38% year-over-year to approximately 140,000 members, reflecting enhanced competitive positioning in the market, with expectations for membership to grow further to between 154,000 and 158,000 in 2026.
- Significant Revenue Growth: Insurance revenue for Q4 2025 was $486 million, a 47% year-over-year increase, while total revenue grew by 40%, showcasing Clover's market leadership, with projected total revenue for 2026 expected to reach between $2.810 billion and $2.920 billion, reflecting a 49% growth.
- Effective Cost Management: Clover reported a consolidated gross profit of $356 million for 2025, with adjusted SG&A as a percentage of total revenue improving to 20% in Q4, indicating ongoing efforts in cost control and operational efficiency, thereby strengthening the foundation for future profitability.
See More
Clover Health Projects 2026 Revenue Above Consensus Estimates
- Optimistic Revenue Outlook: Clover Health projects 2026 revenue between $2.81 billion and $2.92 billion, exceeding the consensus estimate of $2.74 billion, indicating strong confidence in future growth that may attract more investor interest.
- Significant Membership Growth: The company anticipates Medicare Advantage membership to reach 154,000 to 158,000 in 2026, representing approximately 46% year-over-year growth, which highlights substantial progress in market expansion and customer acquisition.
- Increased Cost Pressures: Despite revenue growth, Clover Health's total operating costs surged nearly 50% year-over-year to $537 million in the latest quarter, leading to a widened net loss of $0.10 per share, indicating challenges in profitability.
- Cash Flow Status: As of the end of 2025, the company reported cash, cash equivalents, and investments totaling $319.9 million, down from $437.6 million on December 31, 2024, reflecting the need for careful cash flow management during its expansion phase.
See More
